MARKET NEWS

CordenPharma Completes Acquisition of Three Manufacturing Facilities From Vifor Pharma
Nashville Biosciences Collaborates With Datavant to Accelerate Life Sciences Drug Discovery & Clinical Research
QSAM Biosciences Receives Rare Pediatric Disease Designation From FDA for CycloSam in the Treatment of Osteosarcoma
PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA in Advanced Head & Neck Cancer
Polyplus Acquires e-Zyvec to Expand Expertise in Plasmid DNA Vector Engineering
Biogen Exercises Option to Participate in the Development & Commercialization of a Late-Stage Bispecific Antibody

  FEATURED EDITORIAL

 

  COMPANY PROFILE

 

Backed by over 90 years of experience in parenterals, Baxter’s BioPharma Solutions (BPS) business collaborates with pharmaceutical companies to support commercialization objectives for their molecules. BPS is a premier CMO with a focus on injectable pharmaceutical manufacturing designed to meet complex and traditional sterile manufacturing challenges with confidence of delivery, service, and integrity. BPS can support your pharmaceutical needs with a broad portfolio of sterile fill/finish production capabilities, and our reputation is built on the high-quality products we manufacture for our clients in a cGMP environment. Click here for more.

  EXCLUSIVE ONLINE CONTENT

 

Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis & Secures 5 Million Credit Facility

Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis & Secures $175 Million Credit Facility

Tarsus Pharmaceuticals, Inc. recently announced it has completed enrollment of Saturn-2, the company’s second pivotal Phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) for patients with….

Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune & Inflammatory Diseases from Carna Biosciences

Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune & Inflammatory Diseases from Carna Biosciences

Brickell Biotech, Inc. and Carna Biosciences, Inc. recently announced they have entered into a licensing agreement, whereby Brickell will have the exclusive, worldwide rights to develop and commercialize….

Evoke Pharma & EVERSANA Extend Commercialization Partnership to Further Support GIMOTI

Evoke Pharma & EVERSANA Extend Commercialization Partnership to Further Support GIMOTI

Evoke Pharma, Inc. and EVERSANA Life Science Services, LLC recently announced the extension of their agreement to continue collaborating on the commercialization and distribution of….

Syner-G BioPharma Group Acquires IMPACT; Expands Services for Biotech & Pharma Copanies

Syner-G BioPharma Group Acquires IMPACT; Expands Services for Biotech & Pharma Copanies

Syner-G BioPharma Group recently announced the acquisition of Impact Pharmaceutical Services (IMPACT). Based in Research Triangle Park, NC, IMPACT supports the….

MaxCyte Signs Strategic Platform License With Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs

MaxCyte Signs Strategic Platform License With Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs

MaxCyte, Inc. recently announced the signing of a strategic platform license (SPL) with Intima Bioscience, Inc., a clinical stage biotechnology company developing genetically engineered cell….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

February 16 – Formulation Development
February 23 – ODT/Fast Dissolve